74 related articles for article (PubMed ID: 38472212)
1. Microphthalmia-associated transcription factor in melanoma development and MAP-kinase pathway targeted therapy.
Wellbrock C; Arozarena I
Pigment Cell Melanoma Res; 2015 Jul; 28(4):390-406. PubMed ID: 25818589
[TBL] [Abstract][Full Text] [Related]
2. MITF in melanoma: mechanisms behind its expression and activity.
Hartman ML; Czyz M
Cell Mol Life Sci; 2015 Apr; 72(7):1249-60. PubMed ID: 25433395
[TBL] [Abstract][Full Text] [Related]
3. The MITF/mir-579-3p regulatory axis dictates BRAF-mutated melanoma cell fate in response to MAPK inhibitors.
Liguoro D; Frigerio R; Ortolano A; Sacconi A; Acunzo M; Romano G; Nigita G; Bellei B; Madonna G; Capone M; Ascierto PA; Mancini R; Ciliberto G; Fattore L
Cell Death Dis; 2024 Mar; 15(3):208. PubMed ID: 38472212
[TBL] [Abstract][Full Text] [Related]
4. A melanoma cell state distinction influences sensitivity to MAPK pathway inhibitors.
Konieczkowski DJ; Johannessen CM; Abudayyeh O; Kim JW; Cooper ZA; Piris A; Frederick DT; Barzily-Rokni M; Straussman R; Haq R; Fisher DE; Mesirov JP; Hahn WC; Flaherty KT; Wargo JA; Tamayo P; Garraway LA
Cancer Discov; 2014 Jul; 4(7):816-27. PubMed ID: 24771846
[TBL] [Abstract][Full Text] [Related]
5. miR-579-3p controls melanoma progression and resistance to target therapy.
Fattore L; Mancini R; Acunzo M; Romano G; Laganà A; Pisanu ME; Malpicci D; Madonna G; Mallardo D; Capone M; Fulciniti F; Mazzucchelli L; Botti G; Croce CM; Ascierto PA; Ciliberto G
Proc Natl Acad Sci U S A; 2016 Aug; 113(34):E5005-13. PubMed ID: 27503895
[TBL] [Abstract][Full Text] [Related]
6. Low MITF/AXL ratio predicts early resistance to multiple targeted drugs in melanoma.
Müller J; Krijgsman O; Tsoi J; Robert L; Hugo W; Song C; Kong X; Possik PA; Cornelissen-Steijger PD; Geukes Foppen MH; Kemper K; Goding CR; McDermott U; Blank C; Haanen J; Graeber TG; Ribas A; Lo RS; Peeper DS
Nat Commun; 2014 Dec; 5():5712. PubMed ID: 25502142
[TBL] [Abstract][Full Text] [Related]
7. A PAX3/BRN2 rheostat controls the dynamics of BRAF mediated MITF regulation in MITF
Smith MP; Rana S; Ferguson J; Rowling EJ; Flaherty KT; Wargo JA; Marais R; Wellbrock C
Pigment Cell Melanoma Res; 2019 Mar; 32(2):280-291. PubMed ID: 30277012
[TBL] [Abstract][Full Text] [Related]
8. miR-126-3p down-regulation contributes to dabrafenib acquired resistance in melanoma by up-regulating ADAM9 and VEGF-A.
Caporali S; Amaro A; Levati L; Alvino E; Lacal PM; Mastroeni S; Ruffini F; Bonmassar L; Antonini Cappellini GC; Felli N; Carè A; Pfeffer U; D'Atri S
J Exp Clin Cancer Res; 2019 Jun; 38(1):272. PubMed ID: 31227006
[TBL] [Abstract][Full Text] [Related]
9. Upregulated expression of miR-4443 and miR-4488 in drug resistant melanomas promotes migratory and invasive phenotypes through downregulation of intermediate filament nestin.
Castaldo V; Minopoli M; Di Modugno F; Sacconi A; Liguoro D; Frigerio R; Ortolano A; Di Martile M; Gesualdi L; Madonna G; Capone M; Cirombella R; Catizone A; Del Bufalo D; Vecchione A; Carriero MV; Ascierto PA; Mancini R; Fattore L; Ciliberto G
J Exp Clin Cancer Res; 2023 Nov; 42(1):317. PubMed ID: 38008717
[TBL] [Abstract][Full Text] [Related]
10. Blocking Genomic Instability Prevents Acquired Resistance to MAPK Inhibitor Therapy in Melanoma.
Dharanipragada P; Zhang X; Liu S; Lomeli SH; Hong A; Wang Y; Yang Z; Lo KZ; Vega-Crespo A; Ribas A; Moschos SJ; Moriceau G; Lo RS
Cancer Discov; 2023 Apr; 13(4):880-909. PubMed ID: 36700848
[TBL] [Abstract][Full Text] [Related]
11. Identification of a miRNA-based non-invasive predictive biomarker of response to target therapy in BRAF-mutant melanoma.
Ruggiero CF; Fattore L; Terrenato I; Sperati F; Salvati V; Madonna G; Capone M; Valenti F; Di Martino S; Mandoj C; Liguoro D; Castaldo V; Cafaro G; Simeone E; Vanella V; Russillo M; Conti L; Cuda G; Giannarelli D; Ascierto PA; Mancini R; Ciliberto G
Theranostics; 2022; 12(17):7420-7430. PubMed ID: 36438490
[No Abstract] [Full Text] [Related]
12. Oncosuppressive miRNAs loaded in lipid nanoparticles potentiate targeted therapies in BRAF-mutant melanoma by inhibiting core escape pathways of resistance.
Fattore L; Cafaro G; Di Martile M; Campani V; Sacconi A; Liguoro D; Marra E; Bruschini S; Stoppoloni D; Cirombella R; De Nicola F; Pallocca M; Ruggiero CF; Castaldo V; Catizone A; Del Bufalo D; Viglietto G; Vecchione A; Blandino G; Aurisicchio L; Fanciulli M; Ascierto PA; De Rosa G; Mancini R; Ciliberto G
Oncogene; 2023 Jan; 42(4):293-307. PubMed ID: 36418472
[TBL] [Abstract][Full Text] [Related]
13. Targeting the MITF/APAF-1 axis as salvage therapy for MAPK inhibitors in resistant melanoma.
Carotenuto P; Romano A; Barbato A; Quadrano P; Brillante S; Volpe M; Ferrante L; Tammaro R; Morleo M; De Cegli R; Iuliano A; Testa M; Andreone F; Ciliberto G; Clery E; Troncone G; Palma G; Arra C; Barbieri A; Capone M; Madonna G; Ascierto PA; Lanfrancone L; Indrieri A; Franco B
Cell Rep; 2022 Nov; 41(6):111601. PubMed ID: 36351409
[TBL] [Abstract][Full Text] [Related]
14. MiR-579 Inhibits Lung Adenocarcinoma Cell Proliferation and Metastasis via Binding to CRABP2.
Yi Q; Miao Y; Kong Y; Xu Y; Zhou J; Dong Q; Liu H
Comput Math Methods Med; 2022; 2022():9111681. PubMed ID: 35966249
[TBL] [Abstract][Full Text] [Related]
15. SEMA6A/RhoA/YAP axis mediates tumor-stroma interactions and prevents response to dual BRAF/MEK inhibition in BRAF-mutant melanoma.
Loria R; Laquintana V; Scalera S; Fraioli R; Caprara V; Falcone I; Bazzichetto C; Di Martile M; Rosanò L; Del Bufalo D; Bossi G; Sperduti I; Terrenato I; Visca P; Soddu S; Milella M; Ciliberto G; Falcioni R; Ferraresi V; Bon G
J Exp Clin Cancer Res; 2022 Apr; 41(1):148. PubMed ID: 35440004
[TBL] [Abstract][Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
